Search clinical trials for: Toripalimab (JS001 ) Lenvatinib

Total 871 results

Second Affiliated Hospital, School of Medicine,...

Recruiting

Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer

Colorectal Cancer

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
Tianjin Medical University Cancer Institute and...

Recruiting

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Cervical Cancer | Immunotherapy | Induction Chemotherapy

China
Hebei Medical University Fourth Hospital

Recruiting

Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer (Best-EEC)

Esophageal Carcinoma

China
Fudan University

Recruiting

Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer (SLOT)

Microsatellite Stable Metastatic Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Cervical Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Recurrent Nasopharyngeal Squamous Cell Carcinoma | Toripalimab

China
Sun Yat-sen University

Recruiting

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Solid Tumor | Advanced Cancer

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors

Advanced Solid Tumor

China
Sichuan University

Recruiting

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Advanced Solid Tumor

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Lung Diseases | Thoracic Neoplasms | Non-small Cell Lung Cancer | Pulmonary Sarcomatoid Carcinoma

China
Immunovative Therapies, Ltd.
Mirror Biologics, Inc.

Recruiting

Immunotherapy for Advanced Liver Cancer (ALIVE)

Hepatocellular Carcinoma

Thailand, Malaysia
Ruijin Hospital

Recruiting

Toripalimab Combined With Definitive CCRT for LACC Patients

Cervical Cancer | Immunotherapy | Chemoradiotherapy

China
Sun Yat-sen University

Enrolling by invitation

PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

Anal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage I | Anal Canal Cancer Stage II | Anal Canal Cancer Stage III

China
Peking Union Medical College Hospital

Completed

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Cholangiocarcinoma | Biomarker | Combinational Immunotherapy | Liver Neoplasm Malignant Primary

China
Tianjin Medical University Second Hospital

Recruiting

Tislelizumab Plus Lenvatinib in Stage III-IV RCC (TILUR)

Advanced Kidney Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Stage III Non-small Cell Lung Cancer
Shanghai Zhongshan Hospital
Shanghai Junshi Bioscience Co., Ltd.; OrigiMed

Completed

A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

Melanoma

China
National University Hospital, Singapore
Eisai Co., Ltd.; Tan Tock Seng Hospital

Unknown

Phase II Study of Single Agent Lenvatinib

Breast Cancer

Singapore
Massachusetts Eye and Ear Infirmary
Eisai Inc.

Recruiting

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Advanced Cancer | Differentiated Thyroid Cancer

United States
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Advanced Renal Cell Carcinoma
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Yunfei Yuan

Recruiting

TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial (Thalen)

Hepatocellular Carcinoma | Transarterial Chemoembolization

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Ampullary Carcinoma
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): (SCORPIO)

Gastroesophageal Adenocarcinoma
The First Affiliated Hospital of Zhengzhou University

Recruiting

Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Cancer

China
RenJi Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

Advanced Esophageal Squamous Cell Cancer

China
Eye & ENT Hospital of Fudan University

Recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Locally Advanced Hypopharyngeal Carcinoma

China
Shanghai Zhongshan Hospital
Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
Assistance Publique - Hôpitaux de Paris
Eisai Inc.

Active, not recruiting

Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (LENVABLA)

Hepatocellular Carcinoma

France
Eisai Inc.
Quintiles, Inc.

Completed

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Non-Small Cell Lung Cancer

Belgium, Korea, Republic of, Italy, United States, Hungary, United Kingdom, Czechia
Tianjin Medical University Cancer Institute and...

Recruiting

Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Gastric Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

Resectable Hepatocellular Carcinoma
Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University
The First Hospital of Nanchang

Not yet recruiting

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fudan University
Shanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Ninth People's Hospital... and other collaborators

Recruiting

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Hypopharyngeal Cancer | Larynx Cancer

China
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody for Reactive EBV After BMT

Transplant | EBV Infection | PD-1

China
Zhejiang University

Recruiting

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Colorectal Cancer

China
Beijing Tongren Hospital

Not yet recruiting

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

Solid Tumor

China
Sun Yat-sen University

Unknown

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China

Search clinical trials for: Toripalimab (JS001 ) Lenvatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations